Evidence map›Paper›PMID 40732670›Full record

ArticlePathogens (Basel, Switzerland)2025

Combined Antiviral and Cytoprotective Action of Rosmarinic Acid Against EV-A71 Infection: A Potential Therapeutic Strategy.

Junping Lv, Weishi Lin, Siqi Chao, Jing Xie, Yue Cao, Jinfeng Tie, Yuehua Ke, Binan Lu, Zongran Pang

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Junping LvSchool of Pharmacy, Minzu University of China, Beijing 100081, China.ORCID 0000-0002-2087-5627
Weishi LinCenter for Disease Control and Prevention of PLA, Beijing 100071, China.
Siqi ChaoCenter for Disease Control and Prevention of PLA, Beijing 100071, China.
Jing XieCenter for Disease Control and Prevention of PLA, Beijing 100071, China.
Yue CaoCenter for Disease Control and Prevention of PLA, Beijing 100071, China.
Jinfeng TieCenter for Disease Control and Prevention of PLA, Beijing 100071, China.
Yuehua KeDepartment of Bacteriology, Capital Institute of Pediatrics, 2 Yabao Road, Beijing 100020, China.
Binan LuSchool of Pharmacy, Minzu University of China, Beijing 100081, China.
Zongran PangSchool of Pharmacy, Minzu University of China, Beijing 100081, China.

Funding

National Key R&D Program of China 2021YFC2600300National Natural Science Foundation of China 52370006National Natural Science Foundation of China NSFC No. 22276044
6 · The paper itself

Abstract

Enterovirus A71 (EV-A71), a major etiological agent of hand-foot-mouth disease, can cause severe neurological complications. However, the mechanisms underlying EV-A71-induced cell damage and potential therapeutic strategies remain inadequately understood. Here, we investigated EV-A71 replication dynamics and associated cytopathic effects in nine distinct cell lines, including epithelial, neuronal, immune, and other cell types. Cell viability, membrane integrity, and energy metabolism were assessed using Cell Counting Kit-8 (CCK-8), lactate dehydrogenase (LDH), and adenosine triphosphate (ATP) assays. The antiviral activity of rosmarinic acid (RA), a natural polyphenol, was evaluated by plaque reduction, qPCR, and Western blot. EV-A71 exhibited cell-type-specific replication and cytotoxicity patterns. RA significantly preserved cell viability, reduced LDH release, maintained ATP levels, and suppressed IL-6 expression. Mechanistically, RA inhibited viral replication by downregulating VP1 expression and viral RNA levels. Molecular docking indicated strong binding of RA to the hydrophobic pocket of VP1, potentially disrupting virus-host interactions. Collectively, these findings highlight RA's combined antiviral and cytoprotective potential, supporting its candidacy as a therapeutic agent against EV-A71 infection.

Indexed as

Antiviral AgentsCinnamatesCytoprotectionDepsidesEnterovirus A, HumanEnterovirus InfectionsAnimalsCell LineCell SurvivalHumansMolecular Docking SimulationRosmarinic AcidVirus ReplicationAntiviral AgentsCinnamatesDepsidesRosmarinic Acidcell damageEnterovirus A71inflammatory responserosmarinic acidviral replication

Identifiers

PMID40732670
PMCPMC12299770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.